Metabolic comorbidities and psoriasis

Acta Dermatovenerologica Croatica

Volumn 18, Issue 4, 2010, Pages 297-304

  Gisondi, Paolo ^a   Ferrazzi, Anna ^a   Girolomoni, Giampiero ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Metabolic syndrome; Nonalcoholic fatty liver disease; Obesity; Psoriasis

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB; IMMUNOSUPPRESSIVE AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; GLUCOSE TOLERANCE TEST; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LOW DRUG DOSE; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SMOKING HABIT; SYSTEMIC THERAPY; FATTY LIVER; HYPERTRIGLYCERIDEMIA; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSORIATIC ARTHRITIS; RISK FACTOR;

ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FATTY LIVER; HUMANS; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE AGENTS; INSULIN RESISTANCE; METABOLIC SYNDROME X; METHOTREXATE; OBESITY; PSORIASIS; RISK FACTORS;

EID: 79957559557     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007;25:535-546.
2. Lowes MA, Bowcock AM, Krueger JG. Pat-hogenesis and therapy of psoriasis. Nature 2007;445:866-873.
3. Gisondi P, Girolomoni G, Sampogna F, Tabolli S, Abeni D. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol 2005;15:279-283.
4. Gisondi P, Tinazzi I, El-Dalati G, Gallo M, Biasi D, Barbara LM, et al. Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. Ann Rheum Dis 2008;67:26-30.
5. Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoria-tic arthritis: does the effect change over time? Arthritis Rheum 2007;56:840-849.
6. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009;61:233-239.
7. Ramsay B, O'Reagan T. A survey of the social and psychological effects of psoriasis. Br J Dermatol 2006;118:195-201.
8. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the United Kingdom. Br J Dermatol 2010;163:586-592
9. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010;162:633-636.
10. Ucak S, Ekmekci TR, Basat O, Koslu A, Altun-tas Y. Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venereol 2006;20:517-522.
11. Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007;157:1249-1251.
12. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008;159:895-902.
13. Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008;22:585-589.
14. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-835.
15. Wolf N, Quaranta M, Prescott NJ, Allen M, Smith R, Burden AD, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 2008;45:114-116.
16. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Disli-pidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001;303:33-39.
17. Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profles in untreated and treated psoriasis patients. Atherosclerosis 2007;190:1-9.
18. Mallbris L, Granath F, Hamsten A, Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Der-matol 2006;54:614-621.
19. Campalani E, Allen MH, Fairhurst D, Young HS, Mendonca CO, Burden AD, et al. Apoli-poprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 2006;154:345-352.
20. Chang CF, Lin CC, Chen JY, Yang AH, Shiao MS, Kao JT, et al. Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3. Am J Kidney Dis 2003;42:E18-E23.
21. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-67.
22. Herron MD, Hinckley M, Hoffman MS, Pa-penfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141:1527-34.
23. Lindegård B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986;172:298-304.
24. Naldi L, Addis A, Chimenti S, Giannetti A, Picar-do M, Tomino C, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Pso-care project. Dermatology 2008;217:365-373.
25. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007;167:1670-1675.
26. Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnarsson SI, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous infammation. Br J Dermatol 2008;159:342-350.
27. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008;58:443-446.
28. Gisondi P, Del Giglio M, Di Francesco V, Zam-boni M, Girolomoni G. Weight loss makes obese patients with moderate to severe chronic plaque psoriasis highly responsive to low dose cyclosporine: a randomized, controlled, investigator blinded, clinical trial. Am J Clin Nutr 2008;88:1242-1247.
29. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
30. National Institutes of Health. Third report of the national Cholesterol Education Program Export Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treament Panel III). Executive Summary. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute; 2001. (NIH publ no 01-3670).
31. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Der-matol 2007;157:68-73.
32. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-328.
33. Levi M, Nieuwdorp M, van der Poll T, Stroes E. Metabolic modulation of inflammation-induced activation of coagulation. Semin Thromb He-most 2008;34:26-32.
34. Nieuwdorp M, Stroes ES, Meijers JC, Büller H. Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol 2005;5:155-159.
35. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008;48(Suppl 1):S104-S112.
36. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Ar-terioscler Thromb Vasc Biol 2008;28:27-38.
37. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007;30:1212-1218.
38. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009 (in press).
39. Marchesini G, Marzocchi R, Agostini F, Bugia-nesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005;16:421-427.
40. Loria P, Lonardo A, Bellentani S, Day CP, Mar-chesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis 2007;17:684-698.
41. Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K, et al. Serum cytokine and soluble cy-tokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 2006;26:39-45.
42. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978;99:469-475.
43. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-230.
44. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-1741.
45. Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009;129:2411-2418.
46. Prodanovich S, Ma F, Taylor JR, Pezon C, Fa-sihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52:262-267.
47. Rosenberg P, Urwitz H, Johannesson A, Ros AM, Lindholm J, Kinnman N, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007;46:1111-1118.
48. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-gui- delines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23(Suppl 2):1-70.
49. Stinco G, Piccirillo F, Patrone P. Hypertri-glyceridaemia during treatment with adali-mumab in psoriatic arthritis. Br J Dermatol 2007;157:1273-1274.
50. Franchimont D, Roland S, Gustot T, Quertin-mont E, Toubouti Y, Gervy MC, et al. Impact of infiximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab 2005;90:3510-6.
51. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008;22:341-344.
52. Dixon WG, Watson KD, Lunt M, Hyrich KL. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-2912.
53. Bosello S, Santoliquido A, Zoli A, Di Campli C, Flore R, Tondi P, et al. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with longstanding severe rheumatoid arthritis. Clin Rheumatol 2008;27:833-839.
54. Higa-Sansone G, Szomstein S, Soto F, Bra-secsco O, Cohen C, Rosenthal RJ. Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg 2004;14:1132-1134.